Boston Scientific (NYSE: BSX) today reported data from separate studies backing its Farapulse and Watchman FLX systems.

The objective of this study was to investigate the risk of acute internal jugular, subclavian, and axillary deep venous thrombosis (upper torso DVT [UTDVT]) and pulmonary embolism (PE) and the ...

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSEtm Pulsed Field ...

Her sister rushed her to the hospital where doctors diagnosed her with a pulmonary embolism. Maria was treated with blood thinners which saved her life. A pulmonary embolism is a serious medical ...

Boston Scientific outperforms competitors with strong growth in atrial fibrillation devices and recent acquisitions. Learn ...

Inari Medical (NASDAQ:NARI – Free Report) had its price target increased by Piper Sandler from $52.00 to $80.00 in a report ...

Baird R W cut shares of Inari Medical (NASDAQ:NARI – Free Report) from a strong-buy rating to a hold rating in a research ...

The temporary pause will allow the company to investigate four neurovascular events seen in an external evaluation study.

Acute limb ischemia (ALI) results from a sudden obstruction in the arterial flow to the extremity due to an embolism or thrombosis. Embolic problems result in a greater degree of ischemia than ...